目的 探討鹽酸苯海索片聯(lián)合鹽酸司來吉蘭片治療帕金森病的臨床療效。方法 選取2017年5月-2018年11月在鄭州大學第五附屬醫(yī)院診治的帕金森病患者82例，根據(jù)用藥的差別分為對照組（41例）和治療組（41例）。對照組口服鹽酸司來吉蘭片，5 mg/次，若控制不佳可增至10 mg/次；治療組在對照組的基礎上口服鹽酸苯海索片，開始1~2 mg/d，然后每3~5天增加2 mg，至療效最好而又不出現(xiàn)副反應為止，最大劑量10 mg/d，分3~4次服用。兩組患者均經(jīng)12周治療。觀察兩組患者臨床療效，同時比較治療前后兩組患者MoCA、MMSE、SPOCA-AUT、UPDRS和PDQ-39評分，以及血清白細胞介素-1β（IL-1β）、YKL40、胱抑素C（Cys-C）、可溶性腫瘤壞死因子受體-1（sTNFR-1）、脂聯(lián)素（APN）、尿酸（UA）、一氧化氮合酶（NOS）、超氧化物歧化酶（SOD）、對氧磷脂酶1（PON1）和循環(huán)谷胱甘肽過氧化物酶（CGP）水平。結(jié)果 治療后，對照組臨床有效率為80.49%，顯著低于治療組的97.56%，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療后，兩組患者MoCA評分顯著升高（P<0.05），MMSE、SPOCA-AUT、UPDRS和PDQ-39評分均顯著降低（P<0.05），且治療組患者這些評分改善程度更明顯（P<0.05）。治療后，兩組患者血清IL-1β、YKL40、Cys-C、sTNFR-1水平均明顯下降（P<0.05），APN、UA水平顯著升高（P<0.05），且治療組患者這些血清學指標改善更明顯（P<0.05）。治療后，兩組患者血清NOS、SOD、PON1、CGP水平均顯著升高（P<0.05），且治療組比對照組升高更明顯（P<0.05）。結(jié)論 鹽酸苯海索片聯(lián)合鹽酸司來吉蘭片治療帕金森病效果顯著，可有效促進患者認知功能、神經(jīng)功能、運動功能及生活質(zhì)量的改善。

Objective To investigate the clinical efficacy of benzhexol combined with selegiline in treatment of Parkinson's disease. Methods Patients (82 cases) with Parkinson's disease in the Fifth Affiliated Hospital of Zhengzhou University from May 2017 to November 2018 were divided into control (41 cases) and treatment (41 cases) groups based on different treatments. Patients in the control group were po administered with Selegiline Hydrochloride Tablets, 5 mg/time, if the condition was not well controlled, dosage could be increased to 10 mg/time. Patients in the treatment group were po administered with Benzhexol Hydrochloride Tablets on the basis of the control group, the initial dose was 1-2 mg/d, then increased 2 mg every 3-5 d until the best effect without side effects, and the maximum daily dose was 10 mg, 3-4 times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy was evaluated, and the MoCA, MMSE, SPOCA-AUT, UPDRS and PDQ-39 scores, and the serum levels of IL-1β, YKL40, Cys-C, sTNFR-1, APN UA, NOS, SOD, PON1, and CGP in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 80.49%, which was significantly lower than 97.56% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the MoCA scores in two groups were significantly increased (P<0.05), but the MMSE, SPOCA-AUT, UPDRS and PDQ-39 scores were significantly decreased (P<0.05), and these scores in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the serum levels of IL-1β, YKL40, Cys-C, sTNFR-1 in two groups were significantly decreased (P<0.05), but the APN and UA levels were significantly increased (P<0.05), and these serological indexes in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the NOS, SOD, PON1, and CGP levels in two groups were significantly increased (P<0.05), and which in the treatment group were significantly higher than those in the control group (P<0.05). Conclusion Benzhexol combined with selegiline have remarkable effect in treatment of Parkinson's disease, can effectively promote cognitive, neurological, motor function and quality of life.

R971